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1. Introduction 
Small bowel tumors (SBTs) are rare, accounting for 3-6% of all digestive neoplasms (Gay  
Delvaux, 2008) which is strikingly low when one considers that the small bowel represents 
75% of the length and 90% of the mucosal surface area of the alimentary tract. However, the 
accuracy of this estimate is uncertain because traditional small bowel examining 
methodologies have proved inadequate. 
Gastrointestinal stromal tumors (GISTs) are the most common mesenchimal tumors of the 
gastrointestinal tract (Nowain et al., 2005). Recognized as a distinctive entity in early 1980s 
(Mazur  Clark, 1983), GISTs have been a very active area over the last decade with 
remarkable progress in diagnostic modalities, pathophysiologic understanding, and new 
treatments.  
Until a decade ago, most of the small bowel was out of the range of endoscopic examination. 
The advent of capsule endoscopy (CE) was a major breakthrough for endoscopic diagnosis 
of small bowel diseases (Pennazio, 2005). CE is a safe, painless and sensitive endoscopic 
imaging of the entire small bowel, and several studies have revealed its diagnostic 
superiority over other methods such as push enteroscopy (Mylonaki et al., 2003), small 
bowel follow-through (Costamagna et al., 2002), angiography (Saperas et al., 2007), 
erythrocyte scintigraphy, CT–enterography and magnetic resonance-enterography (Eliakim 
et al., 2004; Golder et al., 2006; Jensen et al., 2011). Several published studies (Arakawa et al., 
2009; Fukumoto et al., 2009; Pasha et al., 2008) showed that CE and double-balloon 
enteroscopy (DBE) are nearly equal in their ability to detect lesions when the entire small 
bowel is examined.  
Following the introduction of CE in clinical practice it was shown that the frequency of SBTs 
is higher than previously published (Cobrin et al., 2006; Estevez et al., 2007), and GISTs are 
the most frequent tumors identified by CE (Rondonotti et al., 2008). Nevertheless, CE lacks 
the ability to obtain biopsy specimens and performed therapeutic procedures, and therefore 
the role of CE in the diagnostic work-up of SBTs, including GISTs is still debated.  
The rising incidence and importance of GISTs represent an interesting challenge for CE 
considering the particular characteristics of these neoplasms. This review will discuss the 
main features of GISTs –one of the most advancing fields of gastrointestinal oncology- with 
particular emphasize on the role of capsule endoscopy in their management. 
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2. Definition 
Gastrointestinal stromal tumors (GISTs) are defined as specific  mesenchymal tumors of 
the gastrointestinal tract arising from the gastrointestinal wall, omentum, mesentery or 
retroperitoneum, that express the KIT (CD117, stem cell factor receptor) protein,  a cell 
membrane receptor with tyrosine kinase activity (Miettinen  Lasota, 2001). Previously, 
GISTs were described as smooth muscle tumors and gastrointestinal autonomic nerve 
tumors (GANTs). The above definition excludes gastrointestinal true smooth muscle 
tumors (leiomyomas, leiomyosarcomas, leiomyoblastomas), neurofibromas and 
schwannomas.  
3. Etiology 
The etiology of GISTs is not known.  Familial GISTs with inheritable KIT or PDGFRA 
(platelet-derived growth factor receptor alpha ) mutations have been identified (Nishida et 
al., 1998). GISTs can also be a component of Carney triad (gastric stromal sarcoma, extra-
adrenal paraganglioma, pulmonary chondroma) (Carney, 1999). A relationship between 
neurofibromatosis 1 and GISTs typically occurring in the small bowel has also been 
postulated (Miettinen et al., 2002). 
4. Epidemiology 
GISTs are the most common mesenchymal tumors of the gastrointestinal tract, with an 
estimated incidence of 10-20 cases per million per year (Nilsson et al., 2005). However, the 
true epidemiology of GISTs has been difficult to determine. GISTs typically occur in older 
adults (age 55 to 65 years), with a mild male predominance in some series (Tran et al., 2005). 
Nevertheless, GISTs have been reported in all ages, including children. GISTs may occur in 
the entire length of the gastrointestinal tract, the most frequent location being the stomach 
(60-70%), followed by small bowel (20-30%), colon and rectum (5%) and esophagus (1%) 
(Miettinen et al., 2006). Within the small bowel, half of the stromal tumors are located in the 
jejunum, 25% in the duodenum and 25% in the ileum. GISTs are the most frequent 
histological type of primary small bowel tumors (Miettinen  Lasota, 2006a).  Occasional, 
GISTs primary in the mesentery and omentum have also been reported (Miettinen et al, 
1999). 
5. Pathogenesis 
The current theory is that an oncogenic  mutation (acquired as a result of unidentified 
factors) on the KIT gene plays the central role in GISTs tumorigenesis. In the 
gastrointestinal tract, KIT (originally also called CD117) is normally expressed by the 
interstitial cells of Cajal, and therefore it has been proposed that GISTs originate from 
these cells (Blay et al., 2005). In the normal cell, the KIT receptor ligand is stem cell factor 
and, when bound, it leads to activation of the receptor and subsequent controlled 
downstream cellular cascades including several of cellular proliferative mechanisms and 
antiapoptotic pathways. In GISTs cells, mutations in the KIT genes lead to activation of 
tyrosine kinase receptor  independent of the receptor ligand. These gain-of-function 
mutations allow uncontrolled cell proliferation and inhibition of normal apoptosis - well-
known steps in carcinogenesis.  
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Mutations of the KIT genes occur in approximately 90% of GISTs. Less than 5% gain-of-
function mutation occur in PDGFRA gene (Heinrich et al., 2003). Nearly 10% of GISTs do 
not have detectable mutation in either KIT or PDGFRA genes.  
6. Pathology 
Small bowel GISTs occur most commonly as a single tumor varying greatly in size from few 
millimeters to several centimeters, and being histologic more often spindled than epitheloid 
type (Figure 1).  
 
 
         
Fig. 1. Small bowel stromal tumor: A) histological picture showing the tumor localized in 
the jejunal submucosa, comprised predominantly of spindle cells (HE stain, 4X); B) 
immunohistochemical staining for KIT (CD 117): strong KIT - positivity in tumor cells 
(images courtesy of M. Danciu, MD) 
Histopathologic appearances of GISTs can be divided into three main categories: 1) spindle 
cell type, containing oval-shaped spindle cells with pale eosinophilic cytoplasm and 
uniform ovoid nuclei; 2) epitheloid cell type, consisting of round cells with variable 
eosinophilic to clear cytoplasm; 3) mixed spindle cells - epitheloid cells type (Corless et al., 
2004). Spindle cell type is the most common (70%), followed by epithelioid  cell (20%), and 
mixed spindle cell-epithelioid pattern (10%). Small bowel GISTs often (40%) contain 
distinctive extracellular collagen fibers (skeinoid fibers) (Min, 1992). 
Macroscopically, GISTs are gray or white tumors, well-circumscribed with a pseudocapsule, 
typically oval and smooth, with normal (rarely dimpled or ulcerated) overlying mucosa 
(Figure 2). 
A B
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Fig. 2. Gastrointestinal stromal tumor at surgery: ulcerated jejunal tumor 
Several pathological and molecular factors have been evaluated to predict biological 
behavior of GISTs. At present, GISTs are classified according to their risks of malignancy 
rather than simply as benign or malignant. A risk assessment scale (Table 1) for the 
malignant potential of GISTs is available after 2001 NIH (National Institute of Health) 
consensus conference (Fletcher et al., 2002), and it is based on two criteria: tumor size and 
mitotic index on histology (number of mitotic figures seen in 50 high-power fields). 
According to this histologic classification, GISTs have a spectrum of malignant behavior 
ranging from “very low risk” (but not zero) to “high risk” (but not certainly malignant). The 
frequency of malignant behavior of GISTs also varies according to site, being higher for 
small bowel tumors (40%) than for gastric ones (20%) (Miettinen  Lasota, 2006b). Survival 
outcomes, tumor-specific deaths, tumor recurrence and metastases are strongly correlated 
with tumor size and mitotic index (Crosby et al., 2001). 
 
Risk level                                              Tumor size (cm)                                           Mitotic count per          
                                                                                                                                          50 HPF*    
Very low                                                       <2                                                                  <5 
Low                                                               2-5                                                                 <5 
Intermediate                                                <5                                                                   6-10 
                                                                       5-10                                                               <5 
High                                                              >5                                                                   >5 
                                                                       >10                                                                any  
                                                                       any                                                                >10 
* HPF: high-power field 
Table 1. NIH criteria for malignant risk in gastrointestinal stromal tumors  
(Fletcher et al., 2002) 
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7. Clinical presentation 
Usually, small bowel GISTs grow slowly and remain asymptomatic for many years. The 
symptoms and signs are not disease-specific. Typically, they are discovered incidentally 
during radiologic or endoscopic investigations and at surgery for other conditions. When 
symptomatic, the most common presenting symptom is gastrointestinal bleeding (melena), 
followed by bowel obstruction. Usually the bleeding is occult, resulting in long-standing 
anemia and associated symptoms before a small bowel GIST is diagnosed. Other presenting 
symptoms are abdominal pain or discomfort, altered bowel function, and abdominal 
fullness. On physical examination, findings based on the tumor size may include a palpable 
abdominal mass. Approximately half of small bowel GISTs have a metastatic component 
(liver, peritoneum) at the time of diagnosis.  
8. Diagnostic procedures 
8.1 Immunohistochemistry 
The final diagnosis of small bowel GISTs depends on histological and immunochemistry 
examinations. The hallmark of small bowel GISTs is their positivity for KIT (CD117), 
confirmed by immunohistochemical staining usually using purified polyclonal antibodies. 
The antibodies against CD34 (hematopoietic progenitor cell antigen) is expressed in about 
50% of small bowel GISTs, and can be used as an adjunct marker for diagnosis. Protein 
kinase C theta are used as secondary immunohistochemical markers  in KIT negative GISTs 
(less than 3%) and for differential diagnosis.  
8.2 Imaging studies 
The diagnosis imaging procedures for small bowel GISTs are similar to those used for other 
small intestinal tumors. Several imaging methods (small bowel follow-through, angiography, 
computed tomography / magnetic resonance – enterography etc) have been used for the 
diagnosis of small bowel GISTs, often with inconclusive results. When diagnostic, at small 
bowel follow-through and computed tomography (CT) enterography, the stromal tumor 
appears as a smooth-lined filling defect in the lumen with well-demarcated borders, 
sometimes with focal area of ulceration (Figure 3). Magnetic resonance (MR) enterography 
does not offer additional information in comparison to CT-enterography. 
The imaging method of choice is contrast-enhanced CT of the abdomen and pelvis 
(Sandrasegaran et al., 2005). As GISTs involve the muscularis propria of the bowel wall, the 
tumor typically appear  as well-circumscribed mass, predominantly extra-luminal. Contrast 
enhancement is usually homogenous within the tumor, though large tumors are 
heterogeneous, with necrotic centers or a cystic component. Less frequently, small bowel 
GISTs occur on CT as intramural masses or intra-luminal polypoid lesions with regular 
contours.  
MR-imaging is helpful in large GISTs that have hemorrhagic and necrotic components at 
contrast enhanced-CT. Solid portions of the tumor show low signal intensity on T1-
weighted images and high signal intensity on T2-weighted images, and enhance of the mass 
after intravenous gadolinium administration. Signal intensity of hemorrhagic areas within 
the tumors can vary from high to low, depending on the age of hemorrhage (Sandrasegaran 
et al., 2005). 
Positron emission tomography (PET scanning) may be helpful in the initial staging or 
evaluation of response to imatinib therapy for GISTs . 
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Fig. 3. CT findings of small bowel stromal tumor: a 43/28/28 mm well-defined  mass with 
central necrosis in the proximal jejunum (image courtesy of D. Negru, MD) 
Endoscopic ultrasonography is helpful in other sites (esophagus, stomach, duodenum, 
rectum), although the method with special probes has been used during single - or double 
balloon - enteroscopy in small bowel GISTs (Matsui et al., 2008).  
Angiography may be the initial radiologic procedure in a patient with significant bleeding; 
angiographically, small bowel GISTs are characterized by irregular or ball-like vessels with 
neovascularity (Fang et al., 2004).  
Double-balloon enteroscopy (DBE) or single balloon enteroscopy have proved effective for 
the diagnosis of small bowel stromal tumors (Lin et al., 2008); typically, they appear as a 
submucosal mass (Figure 4) with normal lining mucosa and may be dimpled or ulcerated. 
Biopsies rarely yield diagnostic material; moreover, biopsy entails the risk of bleeding and 
seeding (National Comprehensive Cancer Network, 2008).  
 
            
Fig. 4. Small bowel stromal tumor: enteroscopy shows submucosal mass with normal 
overlying mucosa, located in distal duodenum (A) and proximal jejunum (B) 
A B 
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GISTs encountered in duodenum and the last centimeters of ileum are diagnosed during 
upper gastrointestinal endoscopy and, respectively, colonoscopy, having the same features 
described at enteroscopy. 
9. Capsule endoscopy  
Traditionally, small bowel stromal tumors have been difficult to diagnose due to their 
nonspecific clinical symptoms, combined with inadequate methodologies for examining the 
small bowel. The advent of CE has revolutionized the investigation of patients with 
suspected SBTs, including GISTs. 
Conventional methods of investigating the small bowel (upper gastrointestinal endoscopy, 
colonoscopy, small bowel follow-through, CT- or MR- enterography) have a low diagnostic 
yield for GISTs. Small bowel is the second most frequent site for GISTs (20-30%), which are 
the most frequent tumor type identified by CE (Rondonotti, 2008). Within the small bowel, 
50% of the stromal tumors are located in the jejunum, 25% in duodenum, and 25% in ileum. 
Usually, all patients with small bowel GISTs undergo several investigations prior to CE 
without a definitive diagnosis being made. The average work-up prior to capsule endoscopy 
is reported to range between 3 and 5 previous negative procedures per patient (Spada et al., 
2008). Thus, the diagnosis of small bowel GISTs is often delayed with the use of traditional 
diagnostic modalities and, consequently, such tumors often are discovered late, 
approximately half having already metastasized at the moment of diagnosis. In this context, 
the sooner we use capsule endoscopy in the investigation of symptomatic patients the 
earlier we can establish a diagnosis, with a positive impact on patient management and 
improved outcome. 
The CE findings of SBTs, and particularly of small bowel GISTs are seldom described in 
details in the published papers probably due to the absence of universally accepted 
terminology, the terms usually being “tumor”, “polypoid mass”, “submucosal mass”, 
“tumor mass”, “bleeding polypoid mass”, “ulcerated mass lesion” and  “irregular ulcer”. 
We have found that a polypoid lesion with normal appearance of overlying mucosa or, 
sometimes, with central ulceration is strongly suggestive of small bowel GIST (Figure 5).    
Nevertheless, any elevated lesion with normal overlying mucosa or a bleeding mucosa 
without a clear identified lesion should to be suspected to hide a GIST. A second CE 
examination may be necessary, or a balloon assisted enteroscopy should be performed when 
the first CE did not reveal a diagnosis and a clinical suspicion persists. During CE reading, 
an inexperienced physician might miss a lesion with no clear-cut features or could 
misinterpret a bleeding lesion as a NSAID ulcer or angiodysplasia. A second reading at a 
slower speed (frame to frame) is mandatory in any lesions, even in those without features of 
tumor. Even an endoscopist with a long experience in traditional endoscopy could also be 
mislead by images provided by CE. A special kind of training requiring patience and visual 
skills rather than manual skills is needed for this time consuming procedure.  
It should be emphasized that CE findings are of uncertain significance in the most of small 
bowel GISTs, and the final diagnosis is established by further diagnostic/therapeutic 
procedures (balloon assisted enteroscopy, surgery) after CE. Moreover, CE cannot reliably 
distinguished between benign and malignant tumors as CE is unable to provide histological 
confirmation to the diagnosis. However, it should be stressed that in case of suspected 
GISTs biopsy entails the risk of bleeding and seeding. Most authors consider that biopsy 
should be avoided in patients with resectable small bowel GISTs (Casali et al., 2006). 
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Fig. 5. Capsule endoscopy findings of small bowel stromal tumors: A) submucosal mass in 
distal duodenum; B) ulcerated jejunal polipoid lesion; C, D) jejunal submucosal mass with 
normal overlying mucosa; E, F) ileal submucosal mass with normal overlying mucosa 
A B
C D
E F
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In all published series about CE in the diagnosis of SBTs, obscure gastrointestinal bleeding was 
the leading indication for capsule endoscopy (Rondonotti  et al., 2008; Soufleris et al., 2008). 
CE is also important to establish the location of small bowel tumors, including GISTs. Most 
frequently, they are located in the jejunum, and it has been agreed that in 90% of cases the 
location as assessed by CE coincides with that found by further diagnostic and/or 
therapeutic work-up (Rondonotti et al., 2008). 
As reported in the literature, the most frequent small bowel tumors types identified by CE 
was small bowel gastrointestinal stromal tumors (Rondonotti et al., 2008). In the largest 
database published so far on SBTs detected by CE, Rondonotti et al (Rondonotti et al., 2008) 
found that GISTs accounted for 32% of all cases. Schwartz and Barkin (Schwartz  Barkin, 
2007) found that small bowel GISTs were the most common benign tumors and CE was the 
diagnostic procedure of choice in patients with suspected small bowel tumors. In our series 
SBTs were detected in 4.9% of patients undergoing CE and the main tumor type was GIST 
(Trifan et al., 2010). Recently, Sidhu and McAlindon (Sidhu  McAlindon, 2011) reported 
that CE is an important modality in the diagnostic work-up of patients with small bowel 
tumors and it has a positive impact on patient management. Similar, Riccioni et al. (Riccioni 
et al., 2010) found CE an effective and sensitive diagnostic modality in GISTs in comparison 
to traditional radiology, having an important role in the algorithm for diagnostic work-up in 
suspected small bowel tumors.  
Capsule endoscopy has some limitations and risks. The first is inability to provide 
histological confirmation of the diagnosis. However, in case of suspected GISTs, biopsy is 
unnecessary as it may cause bleeding and seeding. Another is that CE cannot be 
maneuvered, and it has no means to allow prolonged examination or reexamination of 
questionable or poorly seen areas. Moreover, CE is not a therapeutic tool. Capsule retention 
remains the most significant complication and a major concern to both physicians and 
patients as it has the potential to cause small bowel obstruction which can lead to surgical 
intervention (Lin et al., 2007; Repici et al., 2008). The incidence of capsule retention varies 
widely depending on the indications for the examination. Absence or low rate (1-2%) of 
capsule retention was documented in studies with very strict exclusions criteria (Li et al., 
2008), while high rates (5-21%) occurred in patients with suspected partial small bowel 
obstruction (Cheifetz  Lewis, 2006). Among the main causes of capsule retention are small 
bowel tumors (Toy et al., 2008). So far, there is no safe method of avoiding capsule retention. 
Radiological examination and even the newer imaging techniques entero-CT/MR have a 
low diagnostic yield and tend to underestimate small bowel strictures. Therefore, a patency 
capsule was developed to assess whether patients with suspected small bowel strictures 
could undergo CE. The patency capsule is a self-dissolving capsule, with the same size as 
the conventional capsule. The limitations of the first-generation patency capsule have been 
overcome by the second-generation (the Agile patency capsule), although its role in 
predicting retention needs to be further documented (Herrerias et al., 2008).  Once the 
capsule has been retained only endoscopic (including double-balloon enteroscopy) and 
surgical intervention have been shown to be effective in removing the capsule (Baichi et al., 
2006; Van Weyenberg et al., 2010). Currently, there are different view points regarding 
capsule retentions, some authors considering it as a feared complication of CE (Karagiannis 
et al., 2009), while others have suggested clear benefits from retentions by identifying and 
treating the underlying disease (Mason et al., 2008; Yang et al., 2009). Particularly, capsule 
retention in a patient with small bowel tumor is not a major clinical problem  since the 
tumor will require surgical treatment and the capsule can be retrieved at the time of surgery.  
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10. Prognosis 
Prognosis of GISTs is variable, determined by the malignant potential of the tumor. The best 
documented prognostic markers are tumor size and mitotic activity (Table 1). Tumors that 
show low mitotic frequency (< 5 mitosis per 50 HPF) usually have a benign behavior; 
however, a low mitotic index does not rule out a malignant behavior (Franquemont, 1995). 
A combination of low mitotic rate and small size (< 5 cm) is a more accurate predictor of a 
benign behavior. The small bowel GISTs have a markedly worse prognosis than gastric 
GISTs; thus, small bowel GISTs >10 cm but with a low mitotic rate have 52% metastatic rate, 
whereas gastric GISTs with similar parameters metastasize in 12% of cases (Miettinen  
Lasota, 2006a).  The 5-year survival of all patients with curative resection range from 20% to 
80%. Tumor recurrence after surgical resection is frequent within 2-5 years. The median 
survival after palliative resection is about 10 months (DeMatteo et al., 2000). 
11. Treatment  
11.1 Localized resectable disease 
Surgery is the main type of treatment in patients with localized and potentially resectable 
disease (Ho  Blanke, 2011). The surgeon must avoid intraoperative tumor rupture, which is 
associated with high risk of peritoneal seeding. Small bowel GISTs often require segmental 
resection. Neoadjuvant therapy for patients with resectable disease is not recommended. 
However, preoperative imatinib may be considered for patients with potentially resectable 
disease but with a risk of significant morbidity (Eisenberg  Judson, 2004). The recurrence 
rate remains high after resection of a small bowel GIST, and some questions remain 
regarding post-operative or adjuvant therapy. Imatinib was approved by US Food and Drug 
Administration for patients with resected  GISTs > 3cm in size (Cohen et al., 2010).  
11.2 Unresectable or metastatic disease 
Management of inoperable GISTs has changed radically with discovery and introduction in 
practice of molecularly targeted agents. Imatinib mesylate (Gleevec, Novartis 
Pharmaceuticals, Basel, Switzerland) is the first effective drug in patients with unresectable 
or metastatic GISTs (Cohen et al., 2009). Imatinib is a selective competitive inhibitor of 
protein tyrosine kinases including ABL (Abelson proto-oncogene), KIT and PDGFR. By 
competing with ATP for the kinase-binding site, imatinib inhibits the receptor activation 
and disables downstream cascades (Heinrich et al., 2000). Currently, for patients with 
marginally resectable, metastatic, progressive or recurrent disease, the recommended first-
line therapy is imatinib.  The use of imatinib can be guided by genotyping of KIT mutations: 
KIT exon 11 mutants respond well to imatinib, while KIT exon 9 mutants, which occur 
predominantly in small bowel GISTs are less sensitive to imatinib.  Therefore, in these 
patients  the starting dose of imatinib is 400 mg once daily and then is increased to 800 mg 
daily,  if tolerated, over one month. The present recommendations are for life-long treatment 
with imatinib for patients with metastatic GISTs. The most frequent side effects of imatinib 
include leg edema, nausea, diarrhea, myalgias, fatigue and skin rash. Several clinical trials 
have demonstrated tumor regression and improved survival in patients treated with 
imatinib (Le Cesne et al., 2009).  
Sunitinib malate, a multitargeted tyrosine kinase inhibitor, is considered the standard 
second-line therapy for advanced GISTs (Demetri et al., 2006). It has been used in patients 
who did not respond to imatinib or who could not tolerate imatinib.  
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Several drugs with potential activity against GISTs have been developed and tested in 
recent years. Second-generation tyrosine-kinase inhibitors (nilotinib, dasatinib), sorafenib 
(Nexavar) and other similar drugs (AZD 2171, XL-820) are in clinical testing (Dewaele et al., 
2009; Montemurro et al., 2009). 
12. Conclusion 
Gastrointestinal stromal tumors have been an active area of gastrointestinal oncology over 
the last decade with remarkable progress in diagnostic modalities and new treatments. 
Small bowel is the second most frequent site for GISTs, and their diagnosis is often delayed 
with the use of traditional diagnostic methods. Usually, all patients with small bowel GISTs  
undergo several investigations prior to CE, without a final diagnosis being made. The 
advent of CE has revolutionized the investigation of patients with suspected small bowel 
tumors, including GISTs which are the most frequent tumor type identified by CE.  Despite 
its limitations, CE may be the most reasonable initial diagnostic strategy to evaluate patients 
with suspected  small bowel stromal tumors. In addition, CE has the potential of shortening 
the diagnostic work-up of small bowel stromal tumors. Furthermore, it may be expected 
that CE could identify such tumors at an early stage and thus the prognosis of the patients 
would be improved. Even more, CE could be used to assess  patients after surgery or the 
efficacy of medical therapy.  
13. References 
Arakawa, D., Ohmiya, N., Nakamura, M., et al. (2009). Outcome after enteroscopy for 
patients with obscure gastrointestinal bleeding : Diagnostic comparison between 
double-balloon endoscopy and videocapsule endoscopy. Gastrointest Endosc, Vol. 
69, No. 4, (April 2009), pp. 866-874, ISSN 0016-5107 
Baichi, M.M., Arifuddin, R.M.  Mantry, P.S. (2006). What we have learned from 5 cases of 
permanent capsule retention. Gastrointest Endosc, Vol.64, No. 2, (August 2006), pp. 
283-287, ISSN 0016-5107 
Blay, J.Y., Bonvalot, S., Casali, P., et al. (2005). Consensus meeting for the management of 
gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 
March 2004, under the auspices of ESMO. Ann Oncol, Vol. 16, No. 4, (April 2004), 
pp. 566-578, ISSN 0923-7534 
Carney, J.A. (1999). Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal 
paraganglioma (Carney Triad): natural history, adrenocortical component, and 
possible familial occurrence. Mayo Clin Proc, Vol. 74, No. 6, (June 2006), pp. 543-552, 
ISSN 0025-6196 
Casali, P.G., Jost, L., Sleijfer, S., et al. (2006).Soft tisuue sarcomas. ESMO clinical 
recommendations for diagnosis, treatment and follow up. Ann Oncol, Vol.19, Suppl. 
2,  pp. 90-93, ISSN 0923-7534 
Cheifetz, A.S.  Lewis, B.S. (2006). Capsule endoscopy: is it a complication? J Clin 
Gastroenterol, Vol. 40, No. 8, (September 2006), pp. 688–691, ISSN 0192-0790 
Cobrin, G.M., Pittman, R.H., Lewis, B.S. (2006). Increased diagnostic yield of small bowel 
tumors with capsule endoscopy. Cancer, Vol. 107, No. 1, (July 2006), pp.22-27, ISSN 
1097-0142 
www.intechopen.com
 
New Techniques in Gastrointestinal Endoscopy 
 
160 
Cohen, M.H., Farrell, A.T., Justice, R., et al. (2009).Approval summary: Imatinib mesylate in 
the treatment of metastatic and/or unresectable malignant gastrointestinal stromal 
tumors. The Oncologist, Vol. 14, No. 2, (February 2009), pp. 174-180, ISSN 1083-7159 
Cohen, M.H.,  Cortazar, P.,  Justice, R., et al. (2010). Approval Summary: Imatinib Mesylate 
in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors. The 
Oncologist, Vol. 15, No. 3, (March 2010), pp. 300-307, ISSN 1083-7159 
Corless, C.L., Fletcher, J.A. & Heinrich, M.C. (2004). Biology of gastrointestinal stromal 
tumors. J Clin Oncol, Vol. 22, No. 18, (September 2004), pp. 3813-3825, ISSN 2218-
4333 
Costamagna, G., Shah, S.K., Riccioni, M.E., et al. (2002). A prospective trial comparing small 
bowel radiographs and video capsule endoscopy for suspected small bowel 
disease. Gastroenterology, Vol. 123, No. 4, (October 2002), pp. 999-1005, ISSN 0016-
5085 
Crosby, J.A., Catton, C.N., Davis, A., et al. (2001). Malignant gastrointestinal stromal tumors 
of the small intestine: a review of 50 cases from a prospective database. Ann Surg 
Oncol, Vol.8, No. 1, (January  2001), pp. 50-59, ISSN 1068-9265  
DeMatteo, R.P., Lewis, J.J., Leung, D., et al. (2000). Two hundred gastrointestinal stromal 
tumors: recurrence patterns and prognostic factors for survival. Ann Surg, Vol. 232, 
No. 1, (January 2000), pp. 51-58,  ISSN 0003-4932  
Demetri, G.D., Oosterom, A., Garrett, C.R. et al. (2006). Efficacy and safety of sunitinib in 
patients with advanced gastrointestinal stromal tumour after failure of imatinib: a 
randomised controlled trial. The Lancet, Vol.368, No. 9544, (October 20006), pp. 
1329-1338, ISSN 0140-6736 
Dewaele, B., Wasag, B., Cools, J., et al. (2008). Activity of dasatinib, a dual SRC/ABL kinase 
inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal 
stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res, Vol. 14, No. 
18, (September 2008), pp. 5749-5758, ISSN 1078-0432. 
Eisenberg, B.L.  Judson, I. (2004). Surgery and Imatinib in the Management of GIST: 
Emerging Approaches to Adjuvant and Neoadjuvant Therapy. Annals of Surgical 
Oncology, Vol. 11, No. 5, (May 2004), pp. 465-475, ISSN 1068-9265 
Eliakim, R., Suissa, A., Yasin K, et al. (2004). Wireless capsule video endoscopy compared to 
barium follow-through and computerized tomography scan in patients with 
suspected Crohn's disease. Dig Liver Dis, Vol.36, No. 8, (August 2004), pp. 519-522, 
ISSN 1590-8658 
Estevez, E., Gonzalez-Conde, B., Vazquez-Iglesis, J.L., et al. (2007). Incidence of tumoral 
pathology according to study using capsule  endoscopy for patients with obscure 
gastrointestinal bleeding. Surg Endosc, Vol. 21, No. 10, (October 2010), pp. 1776-
1780, ISSN 0930-2794 
Fang, S.H., Dong, D.J. & Zhang, S.Z. (2004).Angiographic findings of gastrointestinal 
stromal tumor. Jin M. World J Gastroenterol, Vol.10, No. 19, (October 2004), pp. 2905-
2907, ISSN 1007-9327 
Fletcher, C.D., Berman, J.J., Corless, C., et al. (2002). Diagnosis of gastrointestinal stromal 
tumors: A consensus approach. Hum Pathol, Vol. 33, No. 5, (May 2002), pp. 459-65, 
ISSN 2218-4333 
Franquemont, D.W. (1995). Differentiation and risk assessment of gastrointestinal stromal 
tumors. Am J Clin Pathol, Vol. 103, No. 1, (January 1995), pp. 41-47, ISSN 0002-9173  
www.intechopen.com
 
Small Bowel Stromal Tumors: Approach by Capsule Endoscopy 
 
161 
Fukumoto, A., Tanaka, S., Shishido, T., et al. (2009). Comparison of detectability of small-
bowel lesions between capsule endoscopy and double-balloon endoscopy for 
patients with suspected small-bowel disease. Gastrointest  Endosc, Vol. 69, No. 4, 
(April 2009), pp.857-865, ISSN 0016-5107 
Gay, C.  Delvaux, M. (2008). Small-bowel endoscopy. Endoscopy, Vol. 40, No. 2, (February 
2008), pp. 140-146, ISSN 0013-726X 
Golder, S.K., Schreyer, A.G., Endlicher, E., et al. (2006). Comparison of capsule endoscopy 
and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int J 
Colorectal Dis, Vol. 21, No. 2, (March 2006), pp.  97-104, ISSN 0179-1958 
Heinrich, M.C., Griffith, D.J., Druker, B.J., et al (2000). Inhibition of c-kit receptor tyrosine 
kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, Vol. 96, No. 3, 
(August 2000), pp. 925-932, ISSN 0006-4971 
Heinrich, M.C., Corless, C.L., Duensing, A., et al. (2003). PDGFRA activating mutations in 
gastrointestinal stromal tumors. Science, Vol. 299, No. 5607, (January 2003), pp. 708-
710, ISSN 0036-8075  
Herrerias, J.M., Leighton, J.A., Costamagna, G., et al. (2008). Agile patency system eliminates 
risk of capsule retention in patients with known gastrointestinal strictures who 
undergo capsule endoscopy. Gastrointest Endosc, Vol. 67, No. 6, (May 2008), pp. 902-
909, ISSN 0016-5107 
Ho, M.Y.  Blanke, C.D. (2011). Gastrointestinal stromal tumors: disease and treatment 
update. Gastroenterology, Vol. 140, No. 5, (May 2011), pp. 1372-1376, ISSN 0016-5085 
Jensen, M.D., Nathan, T., Rafaelsen, S.R., Kjeldsen, J. (2011). Diagnostic accuracy of capsule 
endoscopy for small bowel Crohn’s disease is superior to that of MR enterography 
or CT enterography. Clin Gastroenterol Hepatol, Vol. 9, No. 2 (February 2001), pp. 
124-129, ISSN 1542-3565 
Karagiannis, S., Faiss, S.  Mavrogiannis, C. (2009). Capsule retention: a feared complication 
of wireless capsule endoscopy. Scand J Gastroenterol, Vol. 44, No. 10, (2009), pp. 
1158-1165, ISSN 0036-5521 
Le Cesne, A., Van Glabbeke, M., Verweij, J., et al. (2009). Absence of progression as assessed 
by response evaluation criteria in solid tumors predicts survival in advanced GI 
stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG 
phase III trial. J Clin Oncol, Vol. 27, No. 24, (august 2009), pp. 3969-3974, ISSN 2218-
4333 
Li, F., Gurudu, S.R., De Petris, G., et al. (2008). Retention of the capsule endoscope: a single-
center experience of 1000 capsule endoscopy procedures. Gastrointest Endosc, Vol. 
68, No. 1, (July 2008), pp. 174-180, ISSN 0016-5107 
Lin, M.B., Yin, L., Li, J.W., et al. (2008). Double-balloon enteroscopy reliably directs surgical 
intervention for patients with small intestinal bleeding. World J Gastroenterol, Vol. 
14, No. 12, (March 2008), pp. 1936-40, ISSN 1007-9327. 
Lin, O.S., Brandabur, J.J., Schembre, D.B., et al. (2007). Acute symptomatic small bowel 
obstruction due to capsule impaction. Gastrointest Endosc, Vol. 65, No. 4, (April 
2007), pp. 725-728, ISSN 0016-5107 
Mason, M., Swain, J., Matthews, B.D., et al. (2008). Use of video capsule endoscopy in the 
setting of recurrent subacute small-bowel obstruction. J Laparoendosc Adv Surg Tech 
A, Vol. 18, No. 5, (October 2008), pp. 713-716, ISSN 1092-6429 
www.intechopen.com
 
New Techniques in Gastrointestinal Endoscopy 
 
162 
Matsui, N., Akahoshi, K., Motomura, Y., et al. (2008). Endosonographic detection of 
dumbbell-shaped jejunal GIST using double balloon enteroscopy. Endoscopy, 
Vol.40,  Suppl 2, (September 2008), E38-39, ISSN 0013-726X 
Mazur, M.T.  Clark, H.B. (1983). Gastric stromal tumors. Reappraisal of histogenesis. Am J 
Surg Pathol, Vol. 7, No. 6, (September 1983), pp. 507–519, ISSN 0147-5185 
Miettinen, M., Monihan, J.M., Sarlomo-Rikala, M., et al. (1999). Gastrointestinal stromal 
tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: 
clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol, 
Vol. 23, No. 9, (September 1999), pp. 1109-1118, ISSN 0147-5185 
Miettinen, M.  Lasota, J. (2001). Gastrointestinal stromal tumors – definition, clinical, 
histological, immunohistochemical, and molecular genetic features and differential 
diagnosis. Virchows Arch, Vol. 438, No. 1, (January 2001), pp. 1-12, ISSN 0340-6075 
Miettinen, M., Majidi, M. & Lasota, J. (2002).  Pathology and diagnostic criteria of 
gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer, Vol. 38, Suppl 5, 
(September 2002), S39-51, ISSN 1359-6349 
Miettinen, M.  Lasota, J. (2006a). Pathology and prognosis of gastrointestinal stromal 
tumors. Semin Diagn Pathol, Vol. 23, No. 2, (May 2006), pp. 70-83, ISSN 0740-2570 
Miettinen, M.  Lasota, J. (2006b). Gastrointestinal stromal tumors: review on morphology, 
molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med, 
Vol.130, No. 10, (October 2006), pp.1466–1478, ISSN 0003-9985 
Miettinen, M., Makhlouf, H., Sobin, L.H.  Lasota, J. (2006). Gastrointestinal stromal tumors 
of the jejunum and ileum: a clinicopathologic, immunohistochemical, and 
molecular genetic study of 906 cases before imatinib with long-term follow-up. Am 
J Surg Pathol, Vol. 30, No. 4, (April 2006), pp. 477-89, ISSN 0147-5185 
Min, K.W. (1992). Small intestinal stromal tumors with skeinoid fibers. Clinicopathological, 
immunohistochemical, and ultrastructural investigations. Am J Surg Pathol, Vol. 16, 
No. 2, (February 1992), pp. 145-155, ISSN 0147-5185 
Montemurro, M., Schöffski, P., Reichardt, P., et al. (2009). Nilotinib in the treatment of 
advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. 
Eur J Cancer, Vol. 45, No. 13, (September 2009), pp. 2293-2297, ISSN 1359-6349 
Mylonaki, M., Fritscher-Ravens, A.,  Swain, P. (2003). Wireless capsule endoscopy: a 
comparison with push enteroscopy in patients with gastroscopy and colonoscopy 
negative gastrointestinal bleeding. Gut, Vol. 52, No. 8, (August 2003), pp.1122-1126, 
ISSN 0017-5749 
NCCN Clinical Practice Guidelines in Oncology. V2.2008. Soft Tissue Sarcomas. 
Nilsson, B., Bümming, P., Meis-Kindblom, J.M., et al. (2005). Gastrointestinal stromal 
tumors: the incidence, prevalence, clinical course, and prognostication in the 
preimatinib mesylate era--a population-based study in western Sweden. Cancer, 
Vol. 103, No. 4, (February 2005), pp. 821-829, SSN 1097-0142 
Nishida, T., Hirota, S., Taniguchi, M., et al. (1998). Familial gastrointestinal stromal tumours 
with germline mutation of the KIT gene. Nat Genet, Vol.19, No. 4, (August 1998),  
pp.323–324, ISSN 1061-4036 
Nowain, A.,  Bhakta, H., Pais, S., Kanel, G.,  Verma, S. (2005). Gastrointestinal stromal 
tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J 
Gastroenterol Hepatol,  Vol. 20, No. 6, (June 2005), pp. 818-824, ISSN 0815-9319 
www.intechopen.com
 
Small Bowel Stromal Tumors: Approach by Capsule Endoscopy 
 
163 
Pasha, S.F., Leighton, J.A., Das, A., et al. (2008). Double-balloon enteroscopy and capsule 
endoscopy have comparable diagnostic yield in small-bowel disease : a meta-
analysis. Clin Gastroenterol Hepatol, Vol. 6, No. 6, (June 2008), pp.:671-676, ISSN 
1542-3565 
Pennazio, M. (2005). Diagnosis of small-bowel diseases in the era of capsule endoscopy. 
Expert Rev Med Devices, Vol. 2, No. 5, (September 2005), pp. 587-598, ISSN 1743-4440 
Repici, A., Barbon, V., De Angelis, C.,  et al. (2008). Acute small-bowel perforation secondary 
to capsule endoscopy. Gastrointest Endosc, Vol. 67, No. 1, (January 2008), pp. 180-
183, ISSN 0016-5107 
Riccioni, M.E., Urgesi, R., Spada, C., et al. (2010). W1191 Increased Diagnostic Yield of Small 
Bowel Tumors With PillCam: the Role of Capsule Endoscopy in Diagnosis and 
Treatment of Gastrointestinal Stromal Tumours (GIST). Italian Single-Centre 
Experience. Gastroenterology, Vol. 138, No. 5, (May 2010),   Suppl 1, S-670-S-671, 
ISSN 0016-5085 
Rondonotti, E., Pennazio, M., Toth, E., et al. (2008). Small-bowel neoplasms in patients 
undergoing video capsule endoscopy : a multicenter European study. Endoscopy, 
Vol. 40, No. 6, (June 2008), pp. 488-495, ISSN 0013-726X 
Sandrasegaran, K., Rajesh, A., Rushing, D.A., et al. (2005). Gastrointestinal stromal tumors: 
CT and MRI findings. Eur Radiol, Vol. 15, No. 7, (July  2005), pp. 1407-1414, ISSN 
0938-7994 
Saperas, E., Dot, J.,  Videla, S., et al. (2007). Capsule endoscopy versus computed 
tomographic or standard angiography for the diagnosis of obscure gastrointestinal 
bleeding. Am J Gastroenterol, Vol. 102, No.  4, (April 2007), pp. 731-737, ISSN 0002-
9270 
Schwartz, G.D. & Barkin, J.S. (2007). Small-bowel tumors detected by Wireless Capsule 
Endoscopy. Dig Dis Sci, Vol. 52, No. 4, (April 2007), pp. 1026-1030,  ISSN 0163-2116 
Sidhu, R.,  McAlindon, M.E. (2011). The use of capsule endoscopy for the diagnosis of 
small bowel tumours: the first single centre UK experience. Gut 2011;60:A91-A92 
doi:10.1136/gut.2011.239301.189, ISSN 1468-3288 
Soufleris, K., Chatzimavroudis, G., Pilpilidis, J., et al. (2008). Five years missed small jejunal 
stromal tumor (GIST) causing recurrent episodes of bleeding: Successful diagnosis 
by capsule endoscopy. Annals of Gastroenterology, Vol. 21, No. 3, pp. 201-204, ISSN 
1108-7471 
Spada, C., Riccioni, M.E., Familiari, P., et al. (2008). Video capsule endoscopy in small-bowel 
tumours: a single centre experience. Scand J Gastroenterol, Vol. 43, No.4, pp.497-505, 
ISSN 0036-5521 
Toy, E., Rojany, M., Sheikh, R., et al. (2008). Capsule endoscopy’s impact on clinical 
management and outcomes: a single-center experience with 145 patients. Am J 
Gastroenterol, Vol. 103, No. 12, (December 2008), pp. 3022-3028, ISSN 0002-9270 
Tran, T., Davila, J.A.  El-Serag, H.B. (2005). The epidemiology of malignant gastrointestinal 
stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol, Vol. 
100, No. 1, (January 2005), pp.  162-168, ISSN 0002-9270 
Trifan, A., Singeap, A.M., Cojocariu, C., et al. (2010). Small bowel tumors in patients 
undergoing capsule endoscopy: a single center experience. J Gastrointestin Liver Dis, 
Vol. 19, No. 1, (March 2010), pp. 21-25, ISSN 1841-8724 
www.intechopen.com
 
New Techniques in Gastrointestinal Endoscopy 
 
164 
Van Weyenberg, S.J., Van Turenhout, S.T., Bouma, G., et al. (2010). Double-balloon 
endoscopy as the primary method for small-bowel video capsule endoscope 
retrieval. Gastrointest Endosc, Vol.71, No. 3, (March 2010), pp. 535-541, ISSN 0016-
5107 
Yang, X.Y., Chen, C.X., Zhang, B.L., et al. (2009). Diagnostic effect of capsule endoscopy in 
31 cases of subacute small bowel obstruction. World J Gastroenterol, Vol. 15, No. 19, 
(May 2009), pp. 2401-2405, ISSN 1007-9327 
www.intechopen.com
New Techniques in Gastrointestinal Endoscopy
Edited by Prof. Oliviu Pascu
ISBN 978-953-307-777-2
Hard cover, 310 pages
Publisher InTech
Published online 30, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
As result of progress, endoscopy has became more complex, using more sophisticated devices and has
claimed a special form. In this moment, the gastroenterologist performing endoscopy has to be an expert in
macroscopic view of the lesions in the gut, with good skills for using standard endoscopes, with good
experience in ultrasound (for performing endoscopic ultrasound), with pathology experience for confocal
examination. It is compulsory to get experience and to have patience and attention for the follow-up of
thousands of images transmitted during capsule endoscopy or to have knowledge in physics necessary for
autofluorescence imaging endoscopy. Therefore, the idea of an endoscopist has changed. Examinations
mentioned need a special formation, a superior level of instruction, accessible to those who have already
gained enough experience in basic diagnostic endoscopy. This is the reason for what these new issues of
endoscopy are presented in this book of New techniques in Gastrointestinal Endoscopy.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Anca Trifan, Ana Maria Singeap and Carol Stanciu (2011). Small Bowel Stromal Tumors: Approach by Capsule
Endoscopy, New Techniques in Gastrointestinal Endoscopy, Prof. Oliviu Pascu (Ed.), ISBN: 978-953-307-777-
2, InTech, Available from: http://www.intechopen.com/books/new-techniques-in-gastrointestinal-
endoscopy/small-bowel-stromal-tumors-approach-by-capsule-endoscopy
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
